MLH1 and cancer: We found an overall 10-year crude survival rate after any cancer diagnosis of 62% in males and 78% in females, and also 70% after any LS-associated cancer, 71% after CRC, and 64% after extracolonic cancer in carriers of MLH1:c.1528C>T founder PV.